.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Pachymic acid production has gained significant attention within the pharmaceutical industry due to its potent anti-tumor and anti-inflammatory properties. This bioactive triterpenoid is primarily found in Poria cocos, a medicinal fungus widely utilized in traditional medicine. However, extracting this compound from natural sources remains difficult and resource-intensive. Consequently, researchers have focused on synthetic biology to find more efficient solutions. A breakthrough study has now identified the CYP5035 gene as a key driver for biosynthetic success.
The research team utilized a multi-omics approach to pinpoint the specific cytochrome P450 gene responsible for the synthesis of this triterpenoid. By treating fungal mycelia with Methyl jasmonate (MeJA), they observed a strong correlation between CYP5035 expression and pachymic acid accumulation. Furthermore, they successfully performed heterologous expression of this gene in Saccharomyces cerevisiae. This process transformed the yeast into a biological factory for the compound.
In addition to gene discovery, the scientists optimized the yeast strain through redox partner enhancement and dynamic flux redirection. These metabolic engineering strategies significantly boosted the overall yield. Therefore, this microbial platform represents a major step toward the green and sustainable manufacture of complex medicinal molecules. This achievement not only clarifies the molecular basis of fungal triterpenoid synthesis but also ensures a reliable supply for future clinical applications.
Pachymic acid is a major bioactive component of Poria cocos. It is highly valued for its anti-tumor, anti-inflammatory, and sedative activities, making it a target for oncology research and natural product pharmacology.
The discovery of the CYP5035 gene allows for the heterologous production of pachymic acid in yeast. This method is more sustainable than traditional extraction, as it does not rely on pine wood-based cultivation or limited natural fungal supplies.
Yeast, specifically Saccharomyces cerevisiae, is a well-understood host for metabolic engineering. It can be modified to express foreign genes, enabling the efficient and scalable production of complex secondary metabolites found in plants and fungi.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional services. Always seek the advice of your physician or other qualified health provider regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers identify the CYP5035 gene to enable the sustainable production of pachymic acid, a bioactive compound with anti-tumor properties, using yeast....
5 months ago
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
Occult maternal malignancy accounts for 3.82% of persistent unreportable NIPT results with genomic noise. Multiple chromosomal aberrations, notably on chromosome 18, warrant thorough oncological evaluation and whole-body MRI to ensure timely maternal diagnosis while preserving fetal care.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
